Tibet Aim Pharm Inc
Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company's products include Miglitol tablets for diabetes; ethnic medicine products, suitable for treating breast lobular hyperplasia, uterine fibroids, and ovarian cysts; gynecology and obstetrics; and NalMefene hydrochloride injection for various acute poisoning, such as alcoh… Read more
Tibet Aim Pharm Inc (002826) - Net Assets
Latest net assets as of September 2025: CN¥802.15 Million CNY
Based on the latest financial reports, Tibet Aim Pharm Inc (002826) has net assets worth CN¥802.15 Million CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.06 Billion) and total liabilities (CN¥256.63 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥802.15 Million |
| % of Total Assets | 75.76% |
| Annual Growth Rate | 23.73% |
| 5-Year Change | 8.5% |
| 10-Year Change | 200.33% |
| Growth Volatility | 51.17 |
Tibet Aim Pharm Inc - Net Assets Trend (2013–2024)
This chart illustrates how Tibet Aim Pharm Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tibet Aim Pharm Inc (2013–2024)
The table below shows the annual net assets of Tibet Aim Pharm Inc from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥745.58 Million | -0.60% |
| 2023-12-31 | CN¥750.06 Million | +0.01% |
| 2022-12-31 | CN¥750.00 Million | +4.15% |
| 2021-12-31 | CN¥720.11 Million | +4.80% |
| 2020-12-31 | CN¥687.15 Million | +5.36% |
| 2019-12-31 | CN¥652.17 Million | +5.46% |
| 2018-12-31 | CN¥618.40 Million | +2.29% |
| 2017-12-31 | CN¥604.53 Million | +8.84% |
| 2016-12-31 | CN¥555.44 Million | +123.74% |
| 2015-12-31 | CN¥248.25 Million | +38.59% |
| 2014-12-31 | CN¥179.12 Million | +149.94% |
| 2013-12-31 | CN¥71.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tibet Aim Pharm Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2266.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥336.75 Million | 45.57% |
| Common Stock | CN¥190.68 Million | 25.80% |
| Other Comprehensive Income | CN¥7.08 Million | 0.96% |
| Other Components | CN¥204.50 Million | 27.67% |
| Total Equity | CN¥739.00 Million | 100.00% |
Tibet Aim Pharm Inc Competitors by Market Cap
The table below lists competitors of Tibet Aim Pharm Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ADTechnology Co.Ltd
KQ:200710
|
$351.60 Million |
|
Fiera Capital Corporation
PINK:FRRPF
|
$351.72 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
$351.90 Million |
|
Better Home & Finance Holding Company
NYSE:BETR
|
$351.94 Million |
|
Guizhou Transp Planning
SHG:603458
|
$351.27 Million |
|
Saimo Electric Co Ltd
SHE:300466
|
$351.06 Million |
|
Shandong Yuma Sun-shading Technology Corp. Ltd.
SHE:300993
|
$350.98 Million |
|
Mirrabooka Investments Ltd
AU:MIR
|
$350.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tibet Aim Pharm Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 745,017,765 to 739,003,677, a change of -6,014,088 (-0.8%).
- Net income of 45,928,802 contributed positively to equity growth.
- Dividend payments of 6,036,545 reduced retained earnings.
- Share repurchases of 50,025,670 reduced equity.
- Other comprehensive income decreased equity by 17,177,723.
- Other factors increased equity by 21,297,048.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥45.93 Million | +6.21% |
| Dividends Paid | CN¥6.04 Million | -0.82% |
| Share Repurchases | CN¥50.03 Million | -6.77% |
| Other Comprehensive Income | CN¥-17.18 Million | -2.32% |
| Other Changes | CN¥21.30 Million | +2.88% |
| Total Change | CN¥- | -0.81% |
Book Value vs Market Value Analysis
This analysis compares Tibet Aim Pharm Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.27x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 43.97x to 5.27x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥0.48 | CN¥21.20 | x |
| 2014-12-31 | CN¥1.33 | CN¥21.20 | x |
| 2015-12-31 | CN¥1.84 | CN¥21.20 | x |
| 2016-12-31 | CN¥3.81 | CN¥21.20 | x |
| 2017-12-31 | CN¥3.20 | CN¥21.20 | x |
| 2018-12-31 | CN¥3.18 | CN¥21.20 | x |
| 2019-12-31 | CN¥3.44 | CN¥21.20 | x |
| 2020-12-31 | CN¥3.62 | CN¥21.20 | x |
| 2021-12-31 | CN¥3.77 | CN¥21.20 | x |
| 2022-12-31 | CN¥3.91 | CN¥21.20 | x |
| 2023-12-31 | CN¥3.87 | CN¥21.20 | x |
| 2024-12-31 | CN¥4.02 | CN¥21.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tibet Aim Pharm Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.21%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.05%
- • Asset Turnover: 0.70x
- • Equity Multiplier: 1.25x
- Recent ROE (6.21%) is below the historical average (10.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 30.30% | 8.91% | 1.44x | 2.35x | CN¥13.20 Million |
| 2014 | 18.07% | 11.14% | 1.08x | 1.50x | CN¥14.46 Million |
| 2015 | 20.15% | 14.42% | 0.87x | 1.60x | CN¥25.20 Million |
| 2016 | 9.97% | 12.25% | 0.70x | 1.16x | CN¥-185.10K |
| 2017 | 10.00% | 15.90% | 0.52x | 1.21x | CN¥23.73K |
| 2018 | 4.08% | 5.17% | 0.64x | 1.23x | CN¥-36.59 Million |
| 2019 | 5.72% | 6.75% | 0.66x | 1.28x | CN¥-27.89 Million |
| 2020 | 5.98% | 6.82% | 0.66x | 1.32x | CN¥-27.62 Million |
| 2021 | 5.92% | 5.86% | 0.88x | 1.15x | CN¥-29.26 Million |
| 2022 | 5.92% | 5.15% | 0.84x | 1.37x | CN¥-30.39 Million |
| 2023 | 2.07% | 2.31% | 0.72x | 1.25x | CN¥-59.12 Million |
| 2024 | 6.21% | 7.05% | 0.70x | 1.25x | CN¥-27.97 Million |
Industry Comparison
This section compares Tibet Aim Pharm Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tibet Aim Pharm Inc (002826) | CN¥802.15 Million | 30.30% | 0.32x | $351.28 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |